OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment
October 08, 2015 at 07:00 AM EDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the European Medicines Agency (EMA) has completed its review of the ...